Charles Schwab Investment Management Inc. Buys 8,397 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)

Charles Schwab Investment Management Inc. raised its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS) by 3.9% in the third quarter, HoldingsChannel.com reports. The firm owned 222,135 shares of the company’s stock after purchasing an additional 8,397 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in iTeos Therapeutics were worth $2,268,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of ITOS. Bank of New York Mellon Corp boosted its holdings in iTeos Therapeutics by 4.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 121,250 shares of the company’s stock valued at $1,799,000 after purchasing an additional 5,409 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of iTeos Therapeutics by 35.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 11,998 shares of the company’s stock valued at $178,000 after buying an additional 3,172 shares in the last quarter. Panagora Asset Management Inc. raised its position in shares of iTeos Therapeutics by 8.9% in the 2nd quarter. Panagora Asset Management Inc. now owns 131,553 shares of the company’s stock valued at $1,952,000 after buying an additional 10,787 shares in the last quarter. Rhumbline Advisers raised its position in shares of iTeos Therapeutics by 8.5% in the 2nd quarter. Rhumbline Advisers now owns 44,861 shares of the company’s stock valued at $666,000 after buying an additional 3,513 shares in the last quarter. Finally, Victory Capital Management Inc. raised its position in shares of iTeos Therapeutics by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 110,389 shares of the company’s stock valued at $1,638,000 after buying an additional 16,629 shares in the last quarter. Institutional investors own 97.16% of the company’s stock.

iTeos Therapeutics Price Performance

ITOS stock opened at $7.68 on Monday. The company has a 50 day simple moving average of $8.74 and a 200 day simple moving average of $12.92. The stock has a market cap of $280.58 million, a price-to-earnings ratio of -2.44 and a beta of 1.37. iTeos Therapeutics, Inc. has a 1 year low of $7.44 and a 1 year high of $18.75.

iTeos Therapeutics (NASDAQ:ITOS) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.18) by $0.13. On average, equities research analysts anticipate that iTeos Therapeutics, Inc. will post -3.46 EPS for the current fiscal year.

Insider Buying and Selling at iTeos Therapeutics

In other iTeos Therapeutics news, CFO Matthew Gall purchased 5,000 shares of the firm’s stock in a transaction on Tuesday, November 19th. The stock was purchased at an average cost of $7.73 per share, for a total transaction of $38,650.00. Following the transaction, the chief financial officer now owns 65,429 shares in the company, valued at $505,766.17. The trade was a 8.27 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 12.50% of the company’s stock.

Analyst Upgrades and Downgrades

ITOS has been the subject of several analyst reports. HC Wainwright restated a “buy” rating and issued a $21.00 target price on shares of iTeos Therapeutics in a research report on Friday. Wedbush restated an “outperform” rating and issued a $25.00 target price on shares of iTeos Therapeutics in a research report on Thursday.

iTeos Therapeutics Profile

Iteos Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity.